Porustobart in combination with toripalimab is intended for the treatment of hepatocellular carcinoma. Credit: KGH / commons.wikimedia.org.

Harbour BioMed has reported results from a Phase Ib clinical trial of porustobart (HBM4003) combined with toripalimab for the treatment of hepatocellular carcinoma (HCC).

The open-label, dose expansion study has been designed to assess the tolerability, safety, PK/PD and preliminary efficacy of the combined therapy in patients with advanced HCC and other solid tumours.

Go deeper with GlobalData

Data Insights

The gold standard of business intelligence.

Find out more

Related Company Profiles

View all

Porustobart 0.45 mg/kg plus toripalimab 240 mg every three weeks was given to 28 patients with advanced HCC in both cohort 1 and cohort 2.

Cohort 1 has selected 16 patients who failed previous anti-VEGFR multikinase inhibitor treatment and did not receive treatment with anti-PD-(L) 1 while cohort 2 enrolled 12 patients who failed previous anti-PD-(L)1 and anti-VEGF(R) treatments.

Objective response rate per RECIST 1.1. is measured as the primary endpoint.

Favorable PK/PD signature was observed in patients treated with porustobart in combination with toripalimab and no noticeable differences in PK between the cohorts were observed.

How well do you really know your competitors?

Access the most comprehensive Company Profiles on the market, powered by GlobalData. Save hours of research. Gain competitive edge.

Company Profile – free sample

Thank you!

Your download email will arrive shortly

Not ready to buy yet? Download a free sample

We are confident about the unique quality of our Company Profiles. However, we want you to make the most beneficial decision for your business, so we offer a free sample that you can download by submitting the below form

By GlobalData
Visit our Privacy Policy for more information about our services, how we may use, process and share your personal data, including information of your rights in respect of your personal data and how you can unsubscribe from future marketing communications. Our services are intended for corporate subscribers and you warrant that the email address submitted is your corporate email address.

Porustobart in combination with toripalimab also showed acceptable safety profile in HCC along with promising anti-tumour activity.

Harbour BioMed founder, chairman and CEO Dr Jingsong Wang said: “We are excited to observe the promising efficacy and safety profile of porustobart and its potential to be developed as a cornerstone therapy in immuno-oncology.

“The continuous breakthrough in clinical studies of porustobart, the first molecule entered into clinical development generated from Harbour Mice HCAb, reflected superb innovation capabilities of our team and vast value of our industry leading technology platforms.

“We are fully committed to advancing the clinical development project of porustobart to address the significant unmet medical needs in multiple solid tumour indications.”